Sandeep Kumar Gupta

Dr. Sandeep Kumar Gupta

Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
JKJayantee Kalita
Jayantee Kalita
DKDhiraj Kumar
Dhiraj Kumar
Sandeep Kumar GuptaSandeep Kumar Gupta
Sandeep Kumar Gupta
PPPrakash C. Pandey
Prakash C. Pandey
RMRoopali Mahajan
Roopali Mahajan
VSVivek Singh
Vivek Singh

2 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JKJayantee Kalita
Jayantee Kalita
Sandeep Kumar GuptaSandeep Kumar Gupta
Sandeep Kumar Gupta
DKDhiraj Kumar
Dhiraj Kumar
FNFiroz M. Nizami
Firoz M. Nizami
PPPrakash Chandra Pandey
Prakash Chandra Pandey
VSVivek Singh
Vivek Singh
Background: In primary supratentorial intracerebral hemorrhage (PSICH), dexamethasone (Dexa) may be effective in reducing perihematoma edema (PHE). We compare the changes in the PHE, hematoma edema complex (HEC), and midline shift (MLS) in patients with PSICH in the Dexa and Non-Dexa groups. Methods: The CT-proven PSICHs were included, and their stroke risk factors, Glasgow Coma Scale (GCS) score, and National Institute of Health Stroke Scale (NIHSS) score were noted. Thirty-one patients received intravenous dexamethasone from day 4 to day 7 of stroke in a dose of 24 mg, 12 mg, and 8 mg daily for 3 days each. Thirty-three patients did not receive dexamethasone. The primary outcome was the change in PHE, HEC, and MLS at 15 days compared to the pre-Dexa CT scan, and the secondary outcomes were death and disability at 3 months and side effects. Results: The Dexa group had a higher volume of ICH, HEC, and PHE, and MLS compared to the Non-Dexa group, although their age, NIHSS and GCS scores were comparable at admission and just before intervention. The Dexa group had a larger reduction in HEC (p = 0.03) and MLS (p < 0.01) compared to the Non-Dexa group. The change in PHE volume was also insignificantly higher in the Dexa group (p = 0.36). At 3 months, the patients with medium (p < 0.001) and large-size hematomas (p < 0.001) in the Dexa group had a good outcome, but this benefit was not observed in small hematomas. Conclusions: In PSICH, dexamethasone after 3 days reduces the HEC and MLS and may have survival and disability benefits especially in medium and large hematomas. A multicentric–randomized–controlled trial may confirm these findings.

4 April 2025 in Journal of Neuroscience and Neurological Disorders
Verified
Journal Article
Open access
JKJayantee Kalita
Jayantee Kalita
DKDhiraj Kumar
Dhiraj Kumar
NGNagendra B Gutti
Nagendra B Gutti
Sandeep Kumar GuptaSandeep Kumar Gupta
Sandeep Kumar Gupta
AMAnadi Mishra
Anadi Mishra
VSVivek Singh
Vivek Singh
Stress in acute stroke may increase mortality and complications, but there is a paucity of information on the efficacy of beta blockers over other anti-hypertensive. To report efficacy of metoprolol over amlodipine in reducing mortality, disability and infections in acute stroke. CT/MRI confirmed stroke patients within 3 days of onset were included whose age was 18 to 75 years. Patients with secondary intracerebral hemorrhage, organ failure, pregnancy, malignancy, and immunosuppressant or on beta-blocker/amlodipine were excluded. Stroke risk factors, Glasgow Coma Scale (GCS) score, National Institute of Health Stroke Scale (NIHSS) score and CT/MRI findings were noted. Patients with a blood pressure of > 160/90 mm of Hg were randomized using 1:1 randomization to metoprolol (25 mg on day 1, 50 mg if BP is not controlled) or amlodipine (2.5 mg on day 1, then 5 mg then 10 mg on, subsequent days if BP is not controlled). Other standard treatment was continued. The primary outcome was mortality at 1 month; secondary outcomes included were in-hospital gastrointestinal hemorrhage, pneumonia, sepsis and 3 months functional outcome based on modified Rankin Scale (mRS). Side effects were noted. 18 (14.4%) patients died; 6 (9.7%) in metoprolol and 12 (19%) in amlodipine (p = 0.20) group. At 3-months, 66 patients had good outcome; 45 (80.4%) in metoprolol and 21 (43.3%) in amlodipine group (p < 0.001). The other secondary outcomes were comparable between the two groups. Metoprolol was withdrawn in 6 patients due to bradycardia, and amlodipine in 5 due to hypotension and in 1 due to allergic reaction. Metoprolol is associated with improved functional outcomes in acute stroke compared to amlodipine.

12 May 2026 in Epilepsy Research
Verified
Journal Article
Closed access
Sandeep Kumar GuptaSandeep Kumar Gupta
Sandeep Kumar Gupta
FNFiroz M. Nizami
Firoz M. Nizami
ADAshish Kant Dubey
Ashish Kant Dubey
JKJayantee Kalita
Jayantee Kalita
ASAlok P. Singh
Alok P. Singh
ZNZafar Neyaz
Zafar Neyaz

1 October 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
Sandeep Kumar GuptaSandeep Kumar Gupta
Sandeep Kumar Gupta
JKJayantee Kalita
Jayantee Kalita
PPPrakash Chandra Pandey
Prakash Chandra Pandey
DKDhiraj Kumar
Dhiraj Kumar
VSVivek Singh
Vivek Singh
RMRoopali Mahajan
Roopali Mahajan
In intracerebral hemorrhage (ICH), an elevated oxidant level may lead to perihematoma edema (PHE) and adversely affect its outcome. We report circulating oxidative stress markers in ICH patients at different time points and their association with PHE on computerized tomographic (CT) scans. A total of 87 patients with CT confirmed ICH within 24 h of ictus were prospectively included, and a follow-up CT scan was performed on day 7. The location and volume of hematoma, hematoma edema complex (HEC), PHE, and intraventricular extension of hemorrhage were noted on both CT scans. Blood samples were collected on days 1, 7, and 15, and reactive oxygen species (ROS), malondialdehyde (MDA), catalase (CAT), and glutathione peroxidase (GPx) levels were measured using a microplate reader. These biomarkers were also measured in 57 age-matched healthy controls. The patients had elevated ROS (p < 0.001) and MDA (p < 0.001) levels, whereas CAT (p < 0.001) and GPx (p < 0.001) levels were reduced compared to the controls. The oxidants remained elevated on day 7 and decreased on day 15 but did not reach the control levels. Furthermore, the CAT and GPx showed recovery on day 7 and day 15 but did not achieve the control levels. ROS (r = 0.28, p = 0.02) and GPx (r = −0.29, p = 0.02) correlated with PHE, suggesting their role in the pathogenesis. The hematoma volume, HEC, and PHE at day 1 correlated with the day 15 CAT level and MDA with PHE. At one month, 15 (17.24%) patients died, 56 (64.36%) had poor recovery, and 16 (18.39%) had good recovery. The patients with higher antioxidant levels had better survival and good outcomes. Future studies may investigate the efficacy of antioxidant therapy in improving clinical outcomes and modulating oxidative stress biomarkers in ICH patients.